What question did this study set out to answer?

The study aims to evaluate the clinical applicability of PRD assessments through clonotypic mass spectrometry in myeloma patients.

December 8, 2025Blood

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

View Full Paper

Ask AI

Bookmark

Authors

Prospective study shows clonotypic mass spectrometry detects minimal residual disease impacting progression-free survival in myeloma patients.

The study aims to evaluate the clinical applicability of PRD assessments through clonotypic mass spectrometry in myeloma patients.
Prospective, multi-center study in patients with newly diagnosed multiple myeloma.
Patients underwent clonotypic mass spectrometry assessments alongside conventional myeloma tests.
Follow-up assessments conducted at regular intervals post-induction and after stem cell transplant.
54 patients successfully identified unique clonotypic peptides from the blood.
83% of patients achieved ≥VGPR post assessment, showing effectiveness in tracking disease.
Concordance evidenced between peripheral and bone marrow MRD assessments, highlighting EasyM's predictive value.

Yang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Prospective study shows clonotypic mass spectrometry detects minimal residual disease impacting progression-free survival in myeloma patients.